Recurrent CNVs Disrupt Three Candidate Genes in Schizophrenia Patients  by Vrijenhoek, Terry et al.
REPORT
Recurrent CNVs Disrupt Three Candidate Genes
in Schizophrenia Patients
Terry Vrijenhoek,1,6 Jacobine E. Buizer-Voskamp,2,3,6 Inge van der Stelt,1 Eric Strengman,3
Genetic Risk and Outcome in Psychosis (GROUP) Consortium7, Chiara Sabatti,4
Ad Geurts van Kessel,1 Han G. Brunner,1 Roel A. Ophoff,2,3,5,* and Joris A. Veltman1
Schizophrenia is a severe psychiatric disease with complex etiology, affecting approximately 1% of the general population. Most genetics
studies so far have focused on disease association with common genetic variation, such as single-nucleotide polymorphisms (SNPs), but
it has recently become apparent that large-scale genomic copy-number variants (CNVs) are involved in disease development as well. To
assess the role of rare CNVs in schizophrenia, we screened 54 patients with deﬁcit schizophrenia using Affymetrix’s GeneChip 250K SNP
arrays. We identiﬁed 90 CNVs in total, 77 of which have been reported previously in unaffected control cohorts. Among the genes
disrupted by the remaining rare CNVs are MYT1L, CTNND2, NRXN1, and ASTN2, genes that play an important role in neuronal func-
tioning but—except for NRXN1—have not been associated with schizophrenia before. We studied the occurrence of CNVs at these four
loci in an additional cohort of 752 patients and 706 normal controls from The Netherlands. We identiﬁed eight additional CNVs, of
which the four that affect coding sequences were found only in the patient cohort. Our study supports a role for rare CNVs in schizo-
phrenia susceptibility and identiﬁes at least three candidate genes for this complex disorder.Schizophrenia [MIM 181500] is a severe psychiatric disease
with complex etiology. It is characterized by a variety of
psychotic symptoms, including delusions and hallucina-
tions, reduced interest and drive, altered emotional reactiv-
ity, and disorganized behavior.1 Despite the facts that
schizophrenia occurs at a high frequency (~1%) in the
general population and that heritability is around 0.80,
genetic studies so far have largely failed to identify suscep-
tibility factors that confer risk alleles for the disease.2,3 This
indicates that schizophrenia is a clinically and genetically
heterogeneous disease. Among the strongest candidate
genes are DISC1 [MIM 605210] and genes in the 22q11
region, such as COMT [MIM 116790] and PRODH [MIM
606810], which have been initially identiﬁed as rare,
high-penetrant cytogenetic variants that either disrupt or
completely delete the genes involved.4,5 Genomicmicroar-
rays allow for the systematic genome-wide analysis of
a more subtle form of cytogenetic variation, i.e., copy-
number variation (CNV): genomic deletions and/or dupli-
cations of 1 kb to 3 Mb in size.6 Recent microarray studies
have identiﬁed many such CNVs in a variety of complex
disorders, including mental retardation,7,8 autism spec-
trum disorder,9–12 and schizophrenia.13–18 It has now
become evident that rare CNVs can have important impli-
cations in the etiology of schizophrenia. Although rare
CNVsmay be related to psychiatric diseases, little is known
about the identity of the genes affected by these variants,
and even less is known about the frequency at which these
individual CNVs occur in the different disorders.19 Here,we combined a genome-wide CNV screen in patients
with deﬁcit schizophrenia, with a targeted, but consider-
ably larger, follow-up study in a general-schizophrenia
patient–control cohort. The deﬁcit subtype of schizophre-
nia is characterized by primary, enduring, negative symp-
toms and is chronic in course.20 Therefore, patients with
such a severe subtype of schizophrenia provide a good ref-
erence set for the detection of CNVs, of which recurrence
assessment and further characterization can be done in
the larger cohort.
We initially performed a genome-wide screen for CNVs
on a small discovery cohort of 54 Dutch patients diag-
nosed with deﬁcit schizophrenia, according to the Diag-
nostic and Statistical Manual of Mental Disorders DSM-
IV-TR,21 for whom extensive phenotypic information
was available from medical records and interviews, includ-
ing the Comprehensive Assessment of History and Symp-
toms (CASH)22 and the Schedule for Deﬁcit Syndrome
(SDS).20 We hybridized genomic DNA of these patients
to Affymetrix’s GeneChip 250K SNP (Nsp) arrays, accord-
ing to standard protocols (GEO accession number:
GSE12714), and identiﬁed genome-wide CNV using the
Copy Number Analyzer for Affymetrix GeneChip
(CNAG) v2.0 software.23 We set the Hidden Markov Model
(HMM) algorithm to calculate copy numbers on the basis
of four consecutive SNPs, with an estimated false-positive
rate of 5%.24 We identiﬁed a total of 90 CNVs, with an
average genomic size of 353 kb (varying from 9 kb to
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(85%, n ¼ 77) were previously reported by Redon et al.6—
who used the same Affymetrix platform to study CNVs
in 270 unaffected HapMap individuals—or observed by
us and listed in our internal CNV database. The latter
contains data from genomic microarray analyses on more
than 400 unaffected individuals of European descent.
The occurrence of these CNVs in these relatively small con-
trol cohorts strongly indicates that they occur frequently
in the general population and do not represent rare geno-
mic variants underlying disease.6 Previously, we and
others7,14–17 have shown that rare CNVs might be respon-
sible for a signiﬁcant proportion of common neurological
disorders. For this reason, we focused on the rare CNVs
as an underlying cause of schizophrenia.
We identiﬁed in our discovery cohort 13 rare CNVs
(Table S2) not described by Redon et al.6 and neither pres-
ent in our internal, unaffected control database nor previ-
ously observed in our diagnostic genome-wide microarray
studies encompassing more than 1300 patients with unex-
plained mental retardation. The HMM algorithm detected
twelve variants, but visual inspection and subsequent
validation revealed one additional CNV that contained
too few SNPs for the algorithm to detect it (12 SNPs in
a 98 kb region on chromosome 9; Figure 1). Some of the
rare variants do overlap with regions listed in the Database
of Genomic Variants (DGV); however, most variants de-
tected in our patients extended beyond those reported in
the DGV. Each of the CNVs was detected in one patient
only, illustrating the rare nature of these variants. Seven
rare variants did not affect any gene, nor were they located
in highly conserved regions. No information on whether
the CNVs are inherited or have arisen de novo in these
patients is available. On the basis of the gene content, we
selected and validated four CNVs by either multiplex liga-
tion-dependent probe ampliﬁcation (MLPA) or genomic
quantitative PCR, essentially as described previously13,25
(Figure 1B, Table S5, Table S6). The four CNVs included
two duplication CNVs in chromosomal regions 2p25.3
and 5p15.2 and two deletions in chromosomal regions
2p16.3 and 9q33.1 (Figure 1). The deletions (237 and
98 kb in size) each affect a single gene: NRXN1 [MIM
600565] on 2p16.3 and ASTN2 on 9q33.1. The duplica-
tions were considerably larger (967 and 930 kb) and affect
four genes on 2p25.3 and seven genes on 5p15.2, respec-
tively. Interestingly, the breakpoints of both duplications
disrupt the terminal parts of two genes: MYT1L at 2p25.3
and CTNND2 [MIM 604275] at 5p15.2. These observations
suggest that, besides dosage variation, these CNVs might
also have disruptive effects, as has been reported be-
fore.17,26 The two genes affected by the deletions, NRXN1
and ASTN2, as well as the genes at the breakpoints of the
two duplications, MYT1L and CTNND2, are highly ex-
pressed in the brain as compared to several other tissues27
(Table S3), and they have all been implicated in neuronal
functioning, adhesion, and migration.28–31
Table 1 displays detailed demographic and diagnostic
information of the four index patients. All patients wereThe Americdiagnosed with schizophrenia of the paranoid type, and
all fulﬁlled the deﬁcit syndrome criteria, according to the
SDS. All four patients were hospitalized and have been
on antipsychotic drugs for several years. At the time of
inclusion, all four patients were severely ill, with consider-
able delusions and hallucinations. Additionally, they dis-
played aggressive behavior during psychosis and fulﬁlled
criteria for formal thought disorder and physical anergia.
In a second-phase analysis, we studied CNVwithin these
four regions in a larger cohort, consisting of 752 additional
patients with schizophrenia and 706 unaffected control
individuals. The patients were recruited from a variety of
psychiatric hospitals and institutions in The Netherlands,
partly coordinated via academic hospitals in Amsterdam,
Groningen, Maastricht, and Utrecht (The Genetic Risk
and Outcome of Psychosis [GROUP] project). All patients
had been diagnosed for subtypes of schizophrenia accord-
ing to the DSM-IV-TR.21 The controls were volunteers and
were all screened for any psychiatric history, the majority
via the CASH. Both cases and controls were of Dutch
descent and they all gave informed consent, as did the
patients of the ﬁrst phase group. The study was approved
by the Ethics Committee of UMC Utrecht and by the
appropriate local institutional review boards at all other
participating hospitals. Genomic DNA of all patients and
controls was hybridized to HumanHap550v3 BeadArray
(Illumina, San Diego, CA, USA) according to standard pro-
tocols. CNVs were included only if they were detected by
two different software packages, PennCNV32 and Quan-
tiSNP.33 We analyzed these data for CNVs in the four can-
didate regions, with boundaries extended to include the
entire coding and noncoding sequence of genes that
were disrupted in the index patients. Within the candidate
regions, we detected CNVs in seven additional patients
and in one control (Figure 1, Table S4, Figure S1). Four of
the CNVs identiﬁed in the patient cohort were located
within the NRXN1 gene at 2p16.3, one of which affected
exonic sequences. In addition, two previously unreported
CNVs were identiﬁed at 2p25.3: a 3.8 Mb duplication
affecting 11 genes, including MYT1L, and a 56 kb duplica-
tion not affecting any known gene. Finally, a 360 kb dupli-
cation that affected part of both the ASTN2 and PAPPA
[MIM 176385] genes was observed in the 9q33.1 region.
The single CNV identiﬁed in the control cohort is an in-
tronic duplication within theNRXN1 gene (Figure 1). Table
S4 displays phenotypic characteristics of these patients;
the control subject with the duplication within the
NRXN1 gene was free of any clinical psychological fea-
tures.
Clearly, most CNVs in our study were observed in
NRXN1; three deletion CNVs affecting coding sequences
and three that were entirely intronic (two duplications
and one deletion). Even though Redon et al.6 observed
one unaffected HapMap individual with a deletion in
NRXN1, deletions in this gene have generally been linked
to neurological disorders, such as mental retardation,34 au-
tism,11,12,35,36 and schizophrenia.14,17 All of thean Journal of Human Genetics 83, 504–510, October 10, 2008 505
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Table 1. Detailed Clinical Features of Four Index Patients with CNVs
Patient 1 Patient 2 Patient 3 Patient 4
Demographics Sex Male Male Female Male
MPA Facial and toe syndactyly - - -
MR Mild MR Yes - Yes
Other - - Stereotypical movements Epilepsy
Diagnostics DSM-IV Diagnosis
(according to CASH)
Paranoid type (295.30) Paranoid type (295.30) Paranoid type (295.30) Paranoid type (295.30)
Age of onset 18 20 20 26
Core symptoms Severe delusions/
hallucinations of sexual/
aggressive content
Isolation, chaotic and
aggressive behavior
Severe delusions/
hallucinations; very
aggressive behavior
Bizarre delusions,
anhedonia, paranoid/
somatic delusions;
aggressive behavior
Fulfilling SDS criteria
(total score if present)*
Yes Yes Yes Yes (12)
Additional information Physical anergia; formal
thought disorder
Physical anergia; formal
thought disorder
Physical anergia; suicidal;
formal thought disorder
Physical anergia; formal
thought disorder
CNV Chromosome 2p25.3 2p16.3 5p15.2 9q33.1
Size (kb) 1014 389 1019 98
Type Duplication Deletion Duplication Deletion
No. of genes 4 1 7 2
Candidate gene MYT1L NRXN1 CTNND2 ASTN2
Gene function Neural cell differentiation,
nervous-system
development
Synaptic formation and
maintenance, axon
guidance
Cell motility, dendritic
branching, neuron
adhesion
Glial-guided neuron
migration, axonal
guidance
* For six items, there can be a score ranging from 0–4.apparently pathogenic deletions reported so far affect the
ﬁrst few exons of theNRXN1 gene, including the promoter
region. In addition, rare missense mutations in exon 1
have been associated with autism.37 In our study, we en-
countered two patients with deletions affecting the pro-
moter region and exon 1, as well as a deletion affecting
exons 8–10. The CNVs in the other two patients and in
one unaffected control were located in intronic sequences
of which any relations to disease cannot as yet be discerned
(Figure 1 and Table S4). Similarly, the larger duplications in
the 2p25.3 region, affecting many genes, are more likely to
be causative than is the 56 kb intergenic duplication ob-
served in this region. The MYT1L gene located in this re-
gion is a member of the myelin transcription factor 1 fam-
ily, which regulates proliferation and differentiation of
oligodendrocytes38 by regulating transcription activity
in the CNS.31 Although MYT1L itself has not previously
been linked to disease, a deletion in its homolog,
MYT1[MIM 600379], was recently observed in a patient
with mental retardation.39 In addition, Law et al.40 hy-
pothesized that MYT1 regulates NRG1 [MIM 142445] ex-
pression in schizophrenia patients. We hypothesize that
the (partial) duplications of MYT1L in patients 1 and 5 inour study cohort might affect this regulatory function in
the CNS by either disruption or dosage effects. For
ASTN2 at 9q33.1, an exonic deletion was observed in pa-
tient 4 and a partial duplication was observed in patient
11, suggesting that disruption of this gene might have
functional consequences. The other gene affected by the
duplication in patient 11—pregnancy-associated plasma
protein A (PAPPA)—is predominantly expressed in the pla-
centa41 and, thus, not likely to be involved in the develop-
ment of schizophrenia. As yet, little is known about
ASTN2—except that it is highly expressed in the brain (Ta-
ble S3)—but its homolog, ASTN [MIM 600904], is known
to play an important role in neuronal migration.29,42 Be-
sides the CNV in 5p15.2 that disrupted the CTNND2
gene in patient 3, no additional aberration was identiﬁed
within this locus, suggesting that CNVs in this locus are ex-
tremely rare and, thus, likely to be pathogenic. Interest-
ingly, CTNND2 is located in the critical region for autism
spectrum disorder43 [MIM 209850]) and mental retarda-
tion44 in Cri du Chat syndrome45 [MIM 123450].
In conclusion, we identiﬁed rare CNVs affecting four
neuronal genes in a selected cohort of 54 schizophrenia
patients. A subsequent targeted but considerably largerFigure 1. Four Rare CNVs in Patients with Schizophrenia
(A) CNAG plots of deletions and duplications in four patients. Upper x axis: Log2 test-over-reference ratios of hybridization signals of
individual SNPs (red dots) and the corresponding HMM algorithm (blue line). Lower x axis: moving average (ten SNPs) result of the
individual Log2-ratios.
(B) MLPA (patients 1, 2, and 4) and qPCR (patient 3) validation of all four CNVs.
(C) Location of duplications and deletions in the 11 patients and the control subject in the respective genomic regions. Displayed are
duplications (blue horizontal lines) and deletions (brown horizontal lines), affected genes (blue), and adjacent known variants from
the Database of Genomic Variants and from studies of unaffected subjects.
The American Journal of Human Genetics 83, 504–510, October 10, 2008 507
follow-up study did not reveal any coding-sequence-affect-
ing CNVs in these loci in the control cohort, whereas four
were found in the patient cohort. In total, we identiﬁed
four small exonic deletions disrupting a part of a gene
implicated in neuronal functioning, as well as three large
duplications with possibly similar disruptive effects. The
frequency of these rare CNVs combined is considerable
in the selected cohort of Dutch patients with deﬁcit schizo-
phrenia (4 of 54 patients, 7% of cases). Even in the larger,
unselected Dutch cohort of schizophrenia patients, we
identiﬁed these rare CNVs in seven out of 752 cases
(0.9%), even though we screened only 5.7 Mb of genomic
sequence. The frequency of rare CNVs affecting genes
reported by Walsh et al.17 in patients with schizophrenia
or schizoaffective disorder is much higher (24% of cases),
but the authors also identiﬁed such variants at consider-
able frequency in controls (5%). Although these results
from us and those from others15–17 demonstrate the rele-
vance of rare CNVs in schizophrenia, they also challenge
the clinical interpretation of nonrecurrent rare CNVs,
even if the CNVs affect genes. Our ﬁndings indicate that
it is important to carefully interpret the individual CNVs
in order to assess their involvement in disease. Large-scale
CNV-based association studies are essential for unraveling
the role of CNVs in disease etiology, but they should take
into consideration that the consequences of intronic or
intragenic CNVs are likely to be different from those of
CNVs that affect coding sequences. Small, single-gene
CNVs are different from larger CNVs affectingmany genes,
and deletions can clearly exert different effects than dupli-
cations. Finally, assessing inheritance patterns of CNVs
and their segregation with disease will be of added value
for establishing the true clinical relevance of this impor-
tant class of genomic variation.
Supplemental Data
Supplemental Data include one ﬁgure and six tables and can be
found with this article online at http://www.ajhg.org/.
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